Development of small-molecule HIV entry inhibitors specifically targeting gp120 or gp41

Current Topics in Medicinal Chemistry

Volumn 16, Issue 10, 2016, Pages 1074-1090

  Lu, Lu ^a   Yu, Fei ^a   Cai, Lifeng ^b   Debnath, Asim K ^c   Jiang, Shibo ^a,c  

^a FUDAN UNIVERSITY   (China)

^b BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^c NEW YORK BLOOD CENTER   (United States)

Author keywords

Entry Inhibitor; Gp120; Gp41; HIV; Viral entry

Indexed keywords

1 BENZOYL 4 [(4,7 DIMETHOXY 1H PYRROLO[2,3 C]PYRIDIN 3 YL)OXOACETYL]PIPERAZINE; 2 ARYL 5 (4 OXO 3 PHENETHYL 2 THIOXOTHIAZOLIDINY LIDENEMETHYL) FURAN; 4 BENZOYL 1 [(4 METHOXY 1H PYRROLO[2,3 B]PYRIDIN 3 YL)OXOACETYL] 2 METHYLPIPERAZINE; 5 [(4 CHLORO 6 PHENYLAMIN 1, 3, 5 TRIAZINE 2 YL) AMINO] 4 HYDROXYL 3 [(4 METHYL 6 SULFOPHENYL)AZO] 2,7 NAPHTHALENE DISULFONIC ACID; 7 [6 PHENYLAMINO 4 [4 [(3,5 DISULFO 8 HYDROXYNAPHTHYL)AZO] 2 METHOXY 5 METHYLPHENYLAMINO] 1,3,5 TRIAZINE 2 YL] 4 HYDROXYL 3 [(2 METHOXY 5 SULFOPHENYL)AZO] 2 NAPHTHALENE SULFONIC ACID; AMIDE; ENFUVIRTIDE; FOSTEMSAVIR; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; N (4 BROMOPHENYL) N' (2,2,6,6 TETRAMETHYLPIPERIDIN 4 YL) OXALAMIDE; N (4 CHLOROPHENYL) N' (2,2,6,6 TETRAMETHYL PIPERIDIN 4 YL) OXALAMID; N PHENYL N' (2,2,6,6 TETRAMETHYL PIPERIDIN 4 YL) OXALAMIDE; TEMSAVIR; UNCLASSIFIED DRUG; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; MOLECULAR LIBRARY;

ANTIVIRAL ACTIVITY; ARTICLE; BINDING AFFINITY; CONFORMATIONAL TRANSITION; CRYSTALLOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENE MUTATION; HIGH THROUGHPUT SCREENING; HUMAN; MEMBRANE PERMEABILITY; SCREENING TEST; SENSITIVITY AND SPECIFICITY; STRUCTURE ACTIVITY RELATION; VIRUS ENTRY; VIRUS REPLICATION; X RAY CRYSTALLOGRAPHY; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM; MOLECULAR LIBRARY; PHARMACOLOGY; SYNTHESIS;

ANTI-HIV AGENTS; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV-1; HUMANS; SMALL MOLECULE LIBRARIES; VIRUS INTERNALIZATION;

EID: 84962481537     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026615666150901114527     Document Type: Article

References (136)

1. Fischl, M. A.; Richman, D. D.; Grieco, M. H.; Gottlieb, M. S.; Volberding, P. A.; Laskin, O. L.; Leedom, J. M.; Groopman, J. E.; Mildvan, D.; Schooley R. T.;. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N. Engl. J. Med., 1987, 317(4), 185-191.
2. Brook, I. Approval of zidovudine (AZT) for acquired immunodeficiency syndrome. A challenge to the medical and pharmaceutical communities. JAMA, 1987, 258(11), 1517.
3. Gulick, R. M.; Mellors, J. W.; Havlir, D.; Eron, J. J.; Gonzalez, C.; McMahon, D.; Richman, D. D.; Valentine, F. T.; Jonas, L.; Meibohm, A.; Emini, E. A.; Chodakewitz, J. A.; Deutsch, P.; Holder, D.; Schleif, W. A.; Condra, J. H. Treatment with Indinavir, Zidovudine, and Lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N. Engl. J. Med., 1997, 337(11), 734-739.
4. Perelson, A. S.; Essunger, P.; Cao, Y.; Vesanen, M.; Hurley, A.; Saksela, K.; Markowitz, M.; Ho, D. D. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature, 1997, 387(6629), 188-191.
5. New York Blood Center. Synthetic peptides as inhibitors of HIV-1. US5,444,044. 1992.
6. Jiang, S.; Lin, K.; Strick, N.; Neurath, A. R. HIV-1 inhibition by a peptide. Nature, 1993, 365(6442), 113.
7. Jiang, S.; Lin, K.; Strick, N.; Neurath, A. R. Inhibition of HIV-1 infection by a fusion domain binding peptide from HIV-1 envelope glycoprotein gp41. Biochem. Biophys. Res. Commun., 1993, 195(2), 533-538.
8. Duke University. Synthetic peptide inhibitors of HIV transmission. US5,464,933. 1993.
9. Wild, C.; Greenwell, T.; Matthews, T. A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res. Hum. Retroviruses., 1993, 9(11), 1051-1053.
10. Wild, C. T.; Shugars, D. C.; Greenwell, T. K.; McDanal, C. B.; Matthews, T. J. Peptides corresponding to a predictive alphahelical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc. Natl. Acad. Sci. USA, 1994, 91(21), 9770-9774.
11. Lu, M.; Blacklow, S. C.; Kim, P. S. A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat. Struct. Biol., 1995, 2(12), 1075-1082.
12. Lu, M.; Kim, P. S. A trimeric structural subdomain of the HIV-1 transmembrane glycoprotein. J. Biomol. Struct. Dyn., 1997, 15(3), 465-471.
13. Chan, D. C.; Fass, D.; Berger, J. M.; Kim, P. S. Core structure of gp41 from the HIV envelope glycoprotein. Cell, 1997, 89(2), 263-273.
14. Rapaport, D.; Ovadia, M.; Shai, Y. A synthetic peptide corresponding to a conserved heptad repeat domain is a potent inhibitor of Sendai virus-cell fusion: an emerging similarity with functional domains of other viruses. EMBO J., 1995, 14(22), 5524-5531.
15. Lambert, D. M.; Barney, S.; Lambert, A. L.; Guthrie, K.; Medinas, R.; Davis, D. E.; Bucy, T.; Erickson, J.; Merutka, G.; Petteway, S. R. Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. Proc. Natl. Acad. Sci. USA., 1996, 93(5), 2186-2191.
16. Wang, E.; Sun, X.; Qian, Y.; Zhao, L.; Tien, P.; Gao, G. F. Both heptad repeats of human respiratory syncytial virus fusion protein are potent inhibitors of viral fusion. Biochem. Biophys. Res. Commun., 2003, 302(3), 469-475.
17. Zhu, J.; Li, P.; Wu, T.; Gao, F.; Ding, Y.; Zhang, C. W.; Rao, Z.; Gao, G. F.; Tien, P. Design and analysis of post-fusion 6-helix bundle of heptad repeat regions from Newcastle disease virus F protein. Protein Eng., 2003, 16(5), 373-379.
18. Zhu, J. Q.; Zhang, C. W.; Rao, Z.; Tien, P.; Gao, G. F. Biochemical and biophysical analysis of heptad repeat regions from the fusion protein of Menangle virus, a newly emergent paramyxovirus. Arch. Virol., 2003, 148(7), 1301-1316.
19. Liu, Y.; Zhu, J.; Feng, M. G.; Tien, P.; Gao, G. F. Six-helix bundle assembly and analysis of the central core of mumps virus fusion protein. Arch. Biochem. Biophys., 2004, 421(1), 143-148.
20. Blacklow, S. C.; Lu, M.; Kim, P. S. A trimeric subdomain of the simian immunodeificiency virous envelope glycoprotein. Biochemistry, 1995, 34(46), 114955-114962.
21. Lombardi, S.; Massi, C.; Indino, E.; La Rosa, C.; Mazzetti, P.; Falcone, M. L.; Rovero, P.; Fissi, A.; Pieroni, O.; Bandecchi, P.; Esposito, F.; Tozzini, F.; Bendinelli, M.; Garzelli, C. Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides. Virology, 1996, 220(2), 274-284.
22. Lee, K. K.; Pessi, A.; Gui, L.; Santoprete, A.; Talekar, A.; Moscona, A.; Porotto, M. Capturing a Fusion Intermediate of Influenza Hemagglutinin with a Cholesterol-conjugated Peptide, a New Antiviral Strategy for Influenza Virus. J. Biol. Chem., 2011, 286(49), 42141-42149.
23. Klein, D. E.; Choi, J. L.; Harrison, S. C. Structure of a dengue virus envelope protein late-stage fusion intermediate. J. Virol., 2013, 87(4), 2287-2293.
24. Weissenhorn, W.; Carfi, A.; Lee, K. H.; Skehel, J. J.; Wiley, D. C. Crystal structure of the Ebola virus membrane fusion subunit, GP2, from the envelope glycoprotein ectodomain. Mol. Cell, 1998, 2(5), 605-616.
25. Miller, E. H.; Harrison, J. S.; Radoshitzky, S. R.; Higgins, C. D.; Chi, X.; Dong, L.; Kuhn, J. H.; Bavari, S.; Lai, J. R.; Chandran, K. Inhibition of Ebola Virus Entry by a C-peptide Targeted to Endosomes. J. Biol. Chem., 2011, 286(18), 15854-15861.
26. Xu, Y.; Gao, S.; Cole, D. K.; Zhu, J.; Su, N.; Wang, H.; Gao, G. F.; Rao, Z. Basis for fusion inhibition by peptides: analysis of the heptad repeat regions of the fusion proteins from Nipah and Hendra viruses, newly emergent zoonotic paramyxoviruses. Biochem. Biophys. Res. Commun., 2004, 315(3), 664-670.
27. Porotto, M.; Doctor, L.; Carta, P.; Fornabaio, M.; Greengard, O.; Kellogg, G. E.; Moscona, A. Inhibition of hendra virus fusion. J. Virol., 2006, 80(19), 9837-9849.
28. Liu, S.; Xiao, G.; Chen, Y.; He, Y.; Niu, J.; Escalante, C. R.; Xiong, H.; Farmar, J.; Debnath, A. K.; Tien, P.; Jiang, S. Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors. Lancet, 2004, 363(9413), 938-947.
29. Tripet, B.; Howard, M. W.; Jobling, M.; Holmes, R. K.; Holmes, K. V.; Hodges, R. S. Structural characterization of the SARScoronavirus spike S fusion protein core. J. Biol. Chem., 2004, 279(20), 20836-20849.
30. Xu, Y.; Lou, Z.; Liu, Y.; Pang, H.; Tien, P.; Gao, G. F.; Rao, Z. Crystal structure of severe acute respiratory syndrome coronavirus spike protein fusion core. J. Biol. Chem., 2004, 279(47), 49414-49419.
31. Zhu, J.; Xiao, G.; Xu, Y.; Yuan, F.; Zheng, C.; Liu, Y.; Yan, H.; Cole, D. K.; Bell, J. I.; Rao, Z.; Tien, P.; Gao, G. F. Following the rule: formation of the 6-helix bundle of the fusion core from severe acute respiratory syndrome coronavirus spike protein and identification of potent peptide inhibitors. Biochem. Biophys. Res. Commun., 2004, 319(1), 283-288.
32. Ingallinella, P.; Bianchi, E.; Finotto, M.; Cantoni, G.; Eckert, D. M.; Supekar, V. M.; Bruckmann, C.; Carfi, A.; Pessi, A. Structural characterization of the fusion-active complex of severe acute respiratory syndrome (SARS) coronavirus. Proc. Natl. Acad. Sci. U. S. A., 2004, 101(23), 8709-8714.
33. Lazzarin, A.; Clotet, B.; Cooper, D.; Reynes, J.; Arasteh, K.; Nelson, M.; Katlama, C.; Stellbrink, H. J.; Delfraissy, J. F.; Lange, J.; Huson, L.; DeMasi, R.; Wat, C.; Delehanty, J.; Drobnes, C.; Salgo, M. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N. Engl. J. Med., 2003, 348(22), 2186-2195.
34. Lalezari, J. P.; Henry, K.; O'Hearn, M.; Montaner, J. S.; Piliero, P. J.; Trottier, B.; Walmsley, S.; Cohen, C.; Kuritzkes, D. R.; Eron, J. J., Jr.; Chung, J.; DeMasi, R.; Donatacci, L.; Drobnes, C.; Delehanty, J.; Salgo, M. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in north and south America. N. Engl. J. Med., 2003, 348(22), 2175-2185.
35. FDA. FDA approves Fuzeon. http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm125 088.htm. 2003.
36. Flores, A.; Quesada, E. Entry inhibitors directed towards glycoprotein gp120: an overview on a promising target for HIV-1 therapy. Curr. Med. Chem., 2012, 20(6), 751-771.
37. Baba, M. Recent advances of CCR5 antagonists. Curr. Opin. HIV. AIDS, 2006, 1(5), 367-372.
38. Westby, M.; van der, R. E. CCR5 antagonists: host-targeted antiviral agents for the treatment of HIV infection, 4 years on. Antivir. Chem. Chemother., 2010, 20(5), 179-192.
39. Chen, W.; Zhan, P.; De, C. E.; Liu, X. Recent progress in small molecule CCR5 antagonists as potential HIV-1 entry inhibitors. Curr. Pharm. Des., 2012, 18(1), 100-112.
40. Barre-Sinoussi, F.; Chermann, J. C.; Rey, F.; Nugeyre, M. T.; Chamaret, S.; Gruest, J.; Dauguet, C.; Axler-Blin, C.; Vezinet- Brun, F.; Rouzioux, C.; Rozenbaum, W.; Montagnier, L. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science, 1983, 220(4599), 868-871.
41. Gallo, R. C.; Salahuddin, S. Z.; Popovic, M.; Shearer, G. M.; Kaplan, M.; Haynes, B. F.; Palker, T. J.; Redfield, R.; Oleske, J.; Safai, B. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science, 1984, 224(4648), 500-503.
42. Luciw, P. A.; Potter, S. J.; Steimer, K.; Dina, D.; Levy, J. A. Molecular cloning of AIDS-associated retrovirus. Nature, 1984, 312(5996), 760-763.
43. Starcich, B. R.; Hahn, B. H.; Shaw, G. M.; McNeely, P. D.; Modrow, S.; Wolf, H.; Parks, E. S.; Parks, W. P.; Josephs, S. F.; Gallo, R. C.;. Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS. Cell, 1986, 45(5), 637-648.
44. Kwon, Y. D.; Finzi, A.; Wu, X.; Dogo-Isonagie, C.; Lee, L. K.; Moore, L. R.; Schmidt, S. D.; Stuckey, J.; Yang, Y.; Zhou, T.; Zhu, J.; Vicic, D. A.; Debnath, A. K.; Shapiro, L.; Bewley, C. A.; Mas cola, J. R.; Sodroski, J. G.; Kwong, P. D. Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops. Proc. Natl. Acad. Sci. U. S. A., 2012, 109(15), 5663-5668.
45. Huang, C. C.; Tang, M.; Zhang, M. Y.; Majeed, S.; Montabana, E.; Stanfield, R. L.; Dimitrov, D. S.; Korber, B.; Sodroski, J.; Wilson, I. A.; Wyatt, R.; Kwong, P. D. Structure of a V3-containing HIV-1 gp120 core. Science, 2005, 310(5750), 1025-1028.
46. Pancera, M.; Majeed, S.; Ban, Y. E. A.; Chen, L.; Huang, C. c.; Kong, L.; Kwon, Y. D.; Stuckey, J.; Zhou, T.; Robinson, J. E.; Schief, W. R.; Sodroski, J.; Wyatt, R.; Kwong, P. D. Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility. Proc. Natl. Acad. Sci., 2010, 107(3), 1166-1171.
47. Weissenhorn, W.; Dessen, A.; Harrison, S. C.; Skehel, J. J.; Wiley, D. C. Atomic Structure of the Ectodomain from HIV-1 gp41. Nature, 1997, 387(6631), 426-428.
48. Tan, K.; Liu, J.; Wang, J.; Shen, S.; Liu, M. Atomic structure of a thermostable subdomain of HIV-1 gp41. Proc. Natl. Acad. Sci. U.S.A., 1997, 94(23), 12303-12308.
49. Ji, H.; Shu, W.; Burling, T.; Jiang, S.; Lu, M. Inhibition of HIV-1 infectivity by the gp41 core: role of a conserved hydrophobic cavity in membrane fusion. J. Virol., 1999, 73(10), 8578-8586.
50. Chan, D. C.; Chutkowski, C. T.; Kim, P. S. Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc. Natl. Acad. Sci. U.S.A., 1998, 95(26), 15613-15617.
51. Dwyer, J. J.; Hasan, A.; Wilson, K. L.; White, J. M.; Matthews, T. J.; Delmedico, M. K. The hydrophobic pocket contributes to the structural stability of the N-terminal coiled coil of HIV gp41 but is not required for six-helix bundle formation. Biochemistry, 2003, 42(17), 4945-4953.
52. Guo, Q.; Ho, H. T.; Dicker, I.; Fan, L.; Zhou, N.; Friborg, J.; Wang, T.; McAuliffe, B. V.; Wang, H. G.; Rose, R. E.; Fang, H.; Scarnati, H. T.; Langley, D. R.; Meanwell, N. A.; Abraham, R.; Colonno, R. J.; Lin, P. F. Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions. J. Virol., 2003, 77(19), 10528-10536.
53. Lin, P. F.; Blair, W.; Wang, T.; Spicer, T.; Guo, Q.; Zhou, N.; Gong, Y. F.; Wang, H. G.; Rose, R.; Yamanaka, G.; Robinson, B.; Li, C. B.; Fridell, R.; Deminie, C.; Demers, G.; Yang, Z.; Zadjura, L.; Meanwell, N.; Colonno, R. A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc. Natl. Acad. Sci. U. S. A., 2003, 100(19), 11013-11018.
54. Chen, B.; Vogan, E. M.; Gong, H.; Skehel, J. J.; Wiley, D. C.; Harrison, S. C. Structure of an unliganded simian immunodeficiency virus gp120 core. Nature, 2005, 433(7028), 834-841.
55. Si, Z.; Madani, N.; Cox, J. M.; Chruma, J. J.; Klein, J. C.; Schon, A.; Phan, N.; Wang, L.; Biorn, A. C.; Cocklin, S.; Chaiken, I.; Freire, E.; Smith, A. B.; Sodroski, J. G. Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins. Proc. Natl. Acad. Sci. U. S. A., 2004, 101(14), 5036-5041.
56. Ho, H. T.; Fan, L.; Nowicka-Sans, B.; McAuliffe, B.; Li, C. B.; Yamanaka, G.; Zhou, N.; Fang, H.; Dicker, I.; Dalterio, R.; Gong, Y. F.; Wang, T.; Yin, Z.; Ueda, Y.; Matiskella, J.; Kadow, J.; Clapham, P.; Robinson, J.; Colonno, R.; Lin, P. F. Envelope conformational changes induced by human immunodeficiency virus type 1 attachment inhibitors prevent CD4 binding and downstream entry events. J. Virol., 2006, 80(8), 4017-4025.
57. Zhou, N.; Fan, L.; Ho, H. T.; Nowicka-Sans, B.; Sun, Y.; Zhu, Y.; Hu, Y.; McAuliffe, B.; Rose, B.; Fang, H.; Wang, T.; Kadow, J.; Krystal, M.; Alexander, L.; Colonno, R.; Lin, P. F. Increased sensitivity of HIV variants selected by attachment inhibitors to broadly neutralizing antibodies. Virology, 2010, 402(2), 256-261.
58. Wang, T.; Yin, Z.; Zhang, Z.; Bender, J. A.; Yang, Z.; Johnson, G.; Yang, Z.; Zadjura, L. M.; D'Arienzo, C. J.; DiGiugno, P. D.; Gesenberg, C.; Yamanaka, G. A.; Gong, Y. F.; Ho, H. T.; Fang, H.; Zhou, N.; McAuliffe, B. V.; Eggers, B. J.; Fan, L.; Nowicka-Sans, B.; Dicker, I. B.; Gao, Q.; Colonno, R. J.; Lin, P. F.; Meanwell, N. A.; Kadow, J. F. Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7- dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane -1,2-dione (BMS- 488043), a drug candidate that demonstrates antiviral activity in HIV-1-infected subjects. J. Med. Chem., 2009, 52(23), 7778-7787.
59. Nowicka-Sans, B.; Gong, Y. F.; McAuliffe, B.; Dicker, I.; Ho, H. T.; Zhou, N.; Eggers, B.; Lin, P. F.; Ray, N.; Wind-Rotolo, M.; Zhu, L.; Majumdar, A.; Stock, D.; Lataillade, M.; Hanna, G. J.; Matiskella, J. D.; Ueda, Y.; Wang, T.; Kadow, J. F.; Meanwell, N. A.; Krystal, M. In vitro antiviral characteristics of HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068. Antimicrob. Agents Chemother., 2012, 56(7), 3498-3507.
60. Li, Z.; Zhou, N.; Sun, Y.; Ray, N.; Lataillade, M.; Hanna, G. J.; Krystal, M. Activity of the HIV-1 attachment inhibitor BMS- 626529, the active component of the prodrug BMS-663068, against CD4-independent viruses and HIV-1 envelopes resistant to other entry inhibitors. Antimicrob. Agents Chemother., 2013, 57(9), 4172-4180.
61. Kadow, J. F.; Ueda, Y.; Meanwell, N. A.; Connolly, T. P.; Wang, T.; Chen, C. P.; Yeung, K. S.; Zhu, J.; Bender, J. A.; Yang, Z.; Parker, D.; Lin, P. F.; Colonno, R. J.; Mathew, M.; Morgan, D.; Zheng, M.; Chien, C.; Grasela, D. Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment 6. Preclinical and human pharmacokinetic profiling of BMS-663749, a phosphonooxymethyl prodrug of the HIV-1 attachment inhibitor 2-(4-benzoyl-1- piperazinyl)-1-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)-2- oxo ethanone (BMS-488043). J. Med. Chem., 2012, 55(5), 2048-2056.
62. Highleyman L. HIV attachment inhibitor BMS-663068 shows good safety and efficacy in phase 2b study. The 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) took place in Boston, USA, 3rd-6th March 2014. 2015.
63. Nowicka-Sans, B.; Gong, Y.F.; Ho, H.T. Antiviral activity of a new small molecule HIV-1 attachment inhibitor, BMS-626529, the parent of BMS663068 (Abstract 518). Poster session presented at: 18th Conference on Retroviruses and Opportunistic Infections; 2012 February 27-March 3; Boston, MA. 2015.
64. Charpentier, C.; Larrouy, L.; Visseaux, B.; Landman, R.; Levittas, M.; Storto, A.; Damond, F.; Yazdanpanah, Y.; Yeni, P.; Brun- Vezinet, F.; Descamps, D. Prevalence of subtype-related polymorphisms associated with in vitro resistance to attachment inhibitor BMS-626529 in HIV-1 'non-B'-infected patients. J. Antimicrob. Chemother. 2012, 67(6), 1459-1461.
65. Zhao, Q.; Ma, L.; Jiang, S.; Lu, H.; Liu, S.; He, Y.; Strick, N.; Neamati, N.; Debnath, A. K. Identification of N-phenyl-N'- (2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4. Virology, 2005, 339(2), 213-225.
66. Schon, A.; Madani, N.; Klein, J. C.; Hubicki, A.; Ng, D.; Yang, X.; Smith, A. B., III; Sodroski, J.; Freire, E. Thermodynamics of binding of a low-molecular-weight CD4 mimetic to HIV-1 gp120. Biochemistry, 2006, 45(36), 10973-10980.
67. Madani, N.; Schn, A.; Princiotto, A. M.; LaLonde, J. M.; Courter, J. R.; Soeta, T.; Ng, D.; Wang, L.; Brower, E. T.; Xiang, S. H.; Do Kwon, Y.; Huang, C. C.; Wyatt, R.; Kwong, P. D.; Freire, E.; Smith A. B.; Sodroski, J. Small-Molecule CD4 Mimics Interact with a Highly Conserved Pocket on HIV-1 gp120. Structure, 2008, 16(11), 1689-1701.
68. Shrivastava, I.; LaLonde, J. M. Enhanced dynamics of HIV gp120 glycoprotein by small molecule binding. Biochemistry, 2011, 50(19), 4173-4183.
69. Yoshimura, K.; Harada, S.; Shibata, J.; Hatada, M.; Yamada, Y.; Ochiai, C.; Tamamura, H.; Matsushita, S. Enhanced exposure of human immunodeficiency virus type 1 primary isolate neutralization epitopes through binding of CD4 mimetic compounds. J. Virol., 2010, 84(15), 7558-7568.
70. LaLonde, J. M.; Elban, M. A.; Courter, J. R.; Sugawara, A.; Soeta, T.; Madani, N.; Princiotto, A. M.; Kwon, Y. D.; Kwong, P. D.; Schon, A.; Freire, E.; Sodroski, J.; Smith, A. B., III. Design, synthesis and biological evaluation of small molecule inhibitors of CD4-gp120 binding based on virtual screening. Bioorg. Med. Chem., 2011, 19(1), 91-101.
71. LaLonde, J. M.; Kwon, Y. D.; Jones, D. M.; Sun, A. W.; Courter, J. R.; Soeta, T.; Kobayashi, T.; Princiotto, A. M.; Wu, X.; Schon, A.; Freire, E.; Kwong, P. D.; Mascola, J. R.; Sodroski, J.; Madani, N.; Smith, A. B., III. Structure-based design, synthesis, and characterization of dual hotspot small-molecule HIV-1 entry inhibitors. J. Med. Chem., 2012, 55(9), 4382-4396.
72. LaLonde, J. M.; Le-Khac, M.; Jones, D. M.; Courter, J. R.; Park, J.; Schon, A.; Princiotto, A. M.; Wu, X.; Mascola, J. R.; Freire, E.; Sodroski, J.; Madani, N.; Hendrickson, W. A.; Smith, A. B.. Structure-Based Design and Synthesis of an HIV-1 Entry Inhibitor Exploiting X-Ray and Thermodynamic Characterization. ACS Med. Chem. Lett., 2013, 4(3), 338-343.
73. Kwon, Y. D.; LaLonde, J. M.; Yang, Y.; Elban, M. A.; Sugawara, A.; Courter, J. R.; Jones, D. M.; Smith, A. B.,; Debnath, A. K.; Kwong, P. D. Crystal structures of HIV-1 gp120 envelope glycoprotein in complex with NBD analogues that target the CD4- binding site. PLoS ONE, 2014, 9(1), e85940.
74. Curreli, F.; Kwon, Y. D.; Zhang, H.; Yang, Y.; Scacalossi, D.; Kwong, P. D.; Debnath, A. K. Binding mode characterization of NBD series CD4-mimetic HIV-1 entry inhibitors by X-ray structure and resistance study. Antimicrob. Agents Chemother., 2014, 58(9), 5478-5491.
75. Curreli, F.; Choudhury, S.; Pyatkin, I.; Zagorodnikov, V. P.; Bulay, A. K.; Altieri, A.; Kwon, Y. D.; Kwong, P. D.; Debnath, A. K. Design, synthesis and antiviral activity of entry inhibitors that target the CD4-binding site of HIV-1. J. Med. Chem., 2012, 55(10), 4764-4775.
76. Herschhorn, A.; Gu, C.; Espy, N.; Richard, J.; Finzi, A. S.; Sodroski, J. G. A broad HIV-1 inhibitor blocks envelope glycoprotein transitions critical for entry. Nat. Chem. Biol., 2014, 10(10), 845-852.
77. Julien, J. P.; Cupo, A.; Sok, D.; Stanfield, R. L.; Lyumkis, D.; Deller, M. C.; Klasse, P. J.; Burton, D. R.; Sanders, R. W.; Moore, J. P.; Ward, A. B.; Wilson, I. A. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science, 2013, Oct 31.[Epub ahead of print]
78. Jiang, S.; Lin, K.; Lu, M. A conformation-specific monoclonal antibody reacting with fusion-active gp41 from the HIV-1 envelope glycoprotein. J. Virol., 1998, 72(12), 10213-10217.
79. Jiang, S.; Lin, K.; Zhang, L.; Debnath, A. K. A screening assay for antiviral compounds targeted to the HIV-1 gp41 core structure using a conformation-specific monoclonal antibody. J. Virol. Methods, 1999, 80(1), 85-96.
80. Debnath, A. K.; Radigan, L.; Jiang, S. Structure-based identification of small molecule antiviral compounds targeted to the gp41 core structure of the human immunodecifiency virus type 1. J. Med. Chem., 1999, 42(17), 3203-3209.
81. Wang, H.; Qi, Z.; Guo, A.; Mao, Q.; Lu, H.; An, X.; Xia, C.; Li, X.; Debnath, A. K.; Wu, S.; Liu, S.; Jiang, S. ADS-J1 inhibits HIV- 1 entry by interacting with the gp41 pocket region and blocking the fusion-active gp41 core formation. Antimicrob. Agents Chemother., 2009, 53(12), 4987-4998.
82. Armand-Ugon, M.; Clotet-Codina, I.; Tintori, C.; Manetti, F.; Clotet, B.; Botta, M.; Este, J. A. The anti-HIV activity of ADS-J1 targets the HIV-1 gp120. Virology, 2005, 343(1), 141-149.
83. Gonzalez-Ortega, E.; Mena, M. P.; Permanyer, M.; Ballana, E.; Clotet, B.; Este, J. A. ADS-J1 inhibits HIV-1 entry by interacting with gp120 and does not block fusion-active gp41 core formation. Antimicrob. Agents Chemother., 2010, 54(10), 4487-4492.
84. Anastassopoulou, C. G.; Ketas, T. J.; Klasse, P. J.; Moore, J. P. Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41. Proc. Natl. Acad. Sci. U.S.A., 2009, 106(13), 5318-5323.
85. Anastassopoulou, C. G.; Ketas, T. J.; Depetris, R. S.; Thomas, A. M.; Klasse, P. J.; Moore, J. P. Resistance of a human immunodeficiency virus type 1 isolate to a small molecule CCR5 inhibitor can involve sequence changes in both gp120 and gp41. Virology, 2011, 413(1), 47-59.
86. Dwyer, J. J.; Wilson, K. L.; Davison, D. K.; Freel, S. A.; Seedorff, J. E.; Wring, S. A.; Tvermoes, N. A.; Matthews, T. J.; Greenberg, M. L.; Delmedico, M. K. Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtideresistant virus. Proc. Natl. Acad. Sci. U.S.A., 2007, 104(31), 12772-12777.
87. Eggink, D.; Bontjer, I.; Langedijk, J. P.; Berkhout, B.; Sanders, R. W. Resistance of human immunodeficiency virus type 1 to a thirdgeneration fusion inhibitor requires multiple mutations in gp41 and is accompanied by a dramatic loss of gp41 function. J. Virol., 2011, 85(20), 10785-10797.
88. Yu, F.; Lu, L.; Liu, Q.; Yu, X.; Wang, L.; He, E.; Zou, P.; Du, L.; Sanders, R. W.; Liu, S.; Jiang, S. ADS-J1 inhibits HIV-1 infection and membrane fusion by targeting the highly conserved pocket in the gp41 NHR-trimer. Biochim. Biophys. Acta, 2014, 1838(5), 1296-1305.
89. Yu, X.; Lu, L.; Cai, L.; Tong, P.; Tan, S.; Zou, P.; Meng, F.; Chen, Y. H.; Jiang, S. Mutations of Gln64 in the HIV-1 gp41 N-terminal heptad repeat render viruses resistant to peptide HIV fusion inhibitors targeting gp41 pocket. J. Virol., 2012, 86(1), 589-593.
90. Lu, L.; Tong, P.; Yu, X.; Pan, C.; Zou, P.; Chen, Y. H.; Jiang, S. HIV-1 variants with a single-point mutation in the gp41 pocket region exhibiting different susceptibility to HIV fusion inhibitors with pocket- or membrane-binding domain. Biochim. Biophys. Acta, 2012, 1818(12), 2950-2957.
91. Chen, X.; Lu, L.; Qi, Z.; Lu, H.; Wang, J.; Yu, X.; Chen, Y.; Jiang, S. Novel recombinant engineered gp41 N-terminal heptad repeat trimers and their potential as anti-HIV-1 therapeutics or microbicides. J. Biol. Chem., 2010, 285(33), 25506-25515.
92. Liu, S.; Boyer-Chatenet, L.; Lu, H.; Jiang, S. Rapid and automated fluorescence-linked immunosorbent assay for high throughput screening of HIV-1 fusion inhibitors targeting gp41. J. Biomol. Screening, 2003, 8(6), 685-693.
93. Jiang, S.; Lu, H.; Liu, S.; Zhao, Q.; He, Y.; Debnath, A. K. Nsubstituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion. Antimicrob. Agents Chemother., 2004, 48(11), 4349-4359.
94. Liu, K.; Lu, H.; Hou, L.; Qi, Z.; Teixeira, C.; Barbault, F.; Fan, B. T.; Liu, S.; Jiang, S.; Xie, L. Design, synthesis, and biological evaluation of N-carboxyphenylpyrrole derivatives as potent HIV fusion inhibitors targeting gp41. J. Med. Chem., 2008, 51(24), 7843-7854.
95. Wang, Y.; Lu, H.; Zhu, Q.; Jiang, S.; Liao, Y. Structure-based design, synthesis and biological evaluation of new Ncarboxyphenylpyrrole derivatives as HIV fusion inhibitors targeting gp41. Bioorg. Med. Chem. Lett., 2010, 20(1), 189-192.
96. Katritzky, A. R.; Tala, S. R.; Lu, H.; Vakulenko, A. V.; Chen, Q. Y.; Sivapackiam, J.; Pandya, K.; Jiang, S.; Debnath, A. K. Design, synthesis, and structure-activity relationship of a novel series of 2- Aryl 5-(4-oxo-3-phenethyl-2-thioxothiazolidin-ylidenemethyl) furans as HIV-1 entry inhibitors. J. Med. Chem., 2009, 52(23), 7631-7639.
97. Jiang, S.; Tala, S. R.; Lu, H.; bo-Dya, N. E.; Avan, I.; Gyanda, K.; Lu, L.; Katritzky, A. R.; Debnath, A. K. Design, synthesis, and biological activity of novel 5-((arylfuran/1H-pyrrol-2-yl)methylene)-2- thioxo-3-(3-(trifluoromethyl)phenyl)thi azolidin-4-ones as HIV-1 fusion inhibitors targeting gp41. J. Med. Chem., 2011, 54(2), 572-579.
98. Cai, L.; Jiang, S. Development of peptide and small-molecule HIV- 1 fusion inhibitors that target gp41. ChemMedChem, 2010, 5(11), 1813-1824.
99. Cai, L.; Gochin, M.; Liu, K. Biochemistry and biophysics of HIV-1 gp41 - membrane interactions and implications for HIV-1 envelope protein mediated viral-cell fusion and fusion inhibitor design. Curr. Top. Med. Chem., 2011, 11(24), 2959-2984.
100. Root, M. J.; Kay, M. S.; Kim, P. S. Protein design of an HIV-1 entry inhibitor. Science, 2001, 291(5505), 884-888.
101. Weissenhorn, W.; Calder, L. J.; Dessen, A.; Laue, T.; Skehel, J. J.; Wiley, D. C. Assembly of a rod-shaped chimera of a trimeric GCN4 zipper and the HIV-1 gp41 ectodomain expressed in Escherichia coli. Proc. Natl. Acad. Sci. U. S. A., 1997, 94(12), 6065-6069.
102. Eckert, D. M.; Malashkevich, V. N.; Kim, P. S. Crystal structure of GCN4-pIQI, a trimeric coiled coil with buried polar residues. J. Mol. Biol., 1998, 284(4), 859-865.
103. Louis, J. M.; Nesheiwat, I.; Chang, L.; Clore, G. M.; Bewley, C. A. Covalent trimers of the internal N-terminal trimeric coiled-coil of gp41 and antibodies directed against them are potent inhibitors of HIV envelope-mediated cell fusion. J. Biol. Chem., 2003, 278(22), 20278-20285.
104. Gochin, M.; Kiplin, G. R.; Case, M. A. A metallopeptide assembly of the HIV-1 gp41 coiled coil is an ideal receptor in fluorescence detection of ligand binding. Angew. Chem. Int. Ed Engl., 2003, 42(43), 5325-5328.
105. Gochin, M.; Savage, R.; Hinckley, S.; Cai, L. A fluorescence assay for rapid detection of ligand binding affinity to HIV-1 gp41. Biol. Chem., 2006, 387(4), 477-483.
106. Cai, L.; Gochin, M. A novel fluorescence intensity screening assay identifies new low molecular weight inhibitors of the gp41 coiled coil domain of HIV-1. Antimicrob. Agents Chemother., 2007, 51(7), 2388-2395.
107. Cai, L.; Balogh, E.; Gochin, M. Stable extended human immunodeficiency virus type 1 gp41 coiled coil as an effective target in an assay for high-affinity fusion inhibitors. Antimicrob. Agents Chemother., 2009, 53(6), 2444-2449.
108. Balogh, E.; Wu, D.; Zhou, G.; Gochin, M. NMR second site screening for structure determination of ligands bound in the hydrophobic pocket of HIV-1 gp41. J. Am. Chem. Soc., 2009, 131(8), 2821-2823.
109. Zhou, G.; Wu, D.; Hermel, E.; Balogh, E.; Gochin, M. Design, synthesis and evaluation of indole compounds as novel inhibitors targeting gp41. Bioorg. Med. Chem. Lett., 2010, 20(5), 1500-1503.
110. Zhou, G.; Wu, D.; Snyder, B.; Ptak, R. G.; Kaur, H.; Gochin, M. Development of indole compounds as small molecule fusion inhibitors targeting HIV-1 glycoprotein-41. J. Med. Chem., 2011, 54(20), 7220-7231.
111. Zhou, G.; Sofiyev, V.; Kaur, H.; Snyder, B. A.; Mankowski, M. K.; Hogan, P. A.; Ptak, R. G.; Gochin, M. Structure-Activity Relationship Studies of Indole-Based Compounds as Small Molecule HIV-1 Fusion Inhibitors Targeting Glycoprotein 41. J. Med. Chem., 2014, 57(12), 5270-5281.
112. Frey, G.; Rits-Volloch, S.; Zhang, X. Q.; Schooley R. T.; Chen, B.; Harrison, S. C. Small molecules that bind the inner core of gp41 and inhibit HIV envelope-mediated fusion. Proc. Natl. Acad. Sci. U. S. A., 2006, 103(38), 13938-13943.
113. Ferrer, M.; Kapoor, T. M.; Strassmaier, T.; Weissenhorn, W.; Skehel, J. J.; Oprian, D.; Schreiber, S. L.; Wiley, D. C.; Harrison, S. C. Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements. Nat. Struct. Biol., 1999, 6(10), 953-960.
114. Zhou, G.; Ferrer, M.; Chopra, R.; Kapoor, T. M.; Strassmaier, T.; Weissenhorn, W.; Skehel, J. J.; Oprian, D.; Schreiber, S. L.; Harrison, S. C.; Wiley, D. C. The structure of an HIV-1 specific cell entry inhibitor in complex with the HIV-1 gp41 trimeric core. Bioorg. Med. Chem., 2000, 8(9), 2219-2227.
115. Orner, B. P.; Ernst, J. T.; Hamilton, A. D. Toward proteomimetics: terphenyl derivatives as structural and functional mimics of extended regions of an alpha-helix. J. Am. Chem. Soc., 2001, 123(22), 5382-5383.
116. Ernst, J. T.; Kutzki, O.; Debnath, A. K.; Jiang, S.; Lu, H.; Hamilton, A. D. Design of a protein surface antagonist based on alphahelix mimicry: inhibition of gp41 assembly and viral fusion. Angew. Chem. Int. Ed Engl., 2002, 41(2), 278-281.
117. Whitby, L. R.; Ando, Y.; Setola, V.; Vogt, P. K.; Roth, B. L.; Boger, D. L. Design, synthesis, and validation of a beta-turn mimetic library targeting protein-protein and peptide-receptor interactions. J. Am. Chem. Soc., 2011, 133(26), 10184-10194.
118. Lang, P. T.; Brozell, S. R.; Mukherjee, S.; Pettersen, E. F.; Meng, E. C.; Thomas, V.; Rizzo, R. C.; Case, D. A.; James, T. L.; Kuntz, I. D. DOCK 6: combining techniques to model RNA-small molecule complexes. RNA, 2009, 15(6), 1219-1230.
119. Holden, P. M.; Kaur, H.; Goyal, R.; Gochin, M.; Rizzo, R. C. Footprint- based identification of viral entry inhibitors targeting HIVgp41. Bioorg. Med. Chem. Lett., 2012, 22(8), 3011-3016.
120. Stewart, K. D.; Huth, J. R.; Ng, T. I.; McDaniel, K.; Hutchinson, R. N.; Stoll, V. S.; Mendoza, R. R.; Matayoshi, E. D.; Carrick, R.; Mo, H.; Severin, J.; Walter, K.; Richardson, P. L.; Barrett, L. W.; Meadows, R.; Anderson, S.; Kohlbrenner, W.; Maring, C.; Kempf, D. J.; Molla, A.; Olejniczak, E. T. Non-peptide entry inhibitors of HIV-1 that target the gp41 coiled-coil pocket. Bioorg. Med. Chem. Lett., 2010, 20(2):612-7(2), 612-617.
121. Yang, J.; Zhang, F.; Li, J.; Chen, G.; Wu, S.; Ouyang, W.; Pan, W.; Yu, R.; Yang, J.; Tien, P. Synthesis and antiviral activities of novel gossypol derivatives. Bioorg. Med. Chem. Lett., 2012, 22(3), 1415-1420.
122. Xu, Y.; Lu, H.; Kennedy, J. P.; Yan, X.; McAllister, L. A.; Yamamoto, N.; Moss, J. A.; Boldt, G. E.; Jiang, S.; Janda, K. D. Evaluation of "credit card" libraries for inhibition of HIV-1 gp41 fusogenic core formation. J Comb. Chem., 2006, 8(4), 531-539.
123. Lu, L.; Liu, Q.; Zhu, Y.; Chan, K. H.; Qin, L.; Li, Y.; Wang, Q.; Chan, J. F.; Du, L.; Yu, F.; Ma, C.; Ye, S.; Yuen, K. Y.; Zhang, R.; Jiang, S. Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. Nat. Commun., 2014, 5(3067).
124. Jiang, S.; Tala, S. R.; Lu, H.; Zou, P.; Avan, I.; Ibrahim, T. S.; bo- Dya, N. E.; Abdelmajeid, A.; Debnath, A. K.; Katritzky, A. R. Design, synthesis, and biological activity of a novel series of 2,5- disubstituted furans/pyrroles as HIV-1 fusion inhibitors targeting gp41. Bioorg. Med. Chem. Lett., 2011, 21(22), 6895-6898.
125. Jiang, S.; Siddiqui, P.; Liu, S. Blocking viral entry: a complementary strategy for HIV therapy. Drug Discov. Today: Ther. Strateg., 2004, 1(4), 497-503.
126. Liu, S.; Jiang, S. High throughput screening and characterization of HIV-1 entry inhibitors targeting gp41: theories and techniques. Curr. Pharm. Des., 2004, 10(15), 1827-1843.
127. Root, M. J.; Hamer, D. H. Targeting therapeutics to an exposed and conserved binding element of the HIV-1 fusion protein. Proc. Natl. Acad. Sci. U. S. A., 2003, 100(9), 5016-5021.
128. Liu, S.; Jing, W.; Cheung, B.; Lu, H.; Sun, J.; Yan, X.; Niu, J.; Farmar, J.; Wu, S.; Jiang, S. HIV gp41 C-terminal heptad repeat contains multifunctional domains: relation to mechanisms of action of anti-HIV peptides. J. Biol. Chem., 2007, 282(13), 9612-9620.
129. Eckert, D. M.; Malashkevich, V. N.; Hong, L. H.; Carr, P. A.; Kim, P. S. Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket. Cell, 1999, 99(1), 103-115.
130. Welch, B. D.; VanDemark, A. P.; Heroux, A.; Hill, C. P.; Kay, M. S. Potent D-peptide inhibitors of HIV-1 entry. Proc. Natl. Acad. Sci. U.S.A., 2007, 104(43), 16828-16833.
131. Welch, B. D.; Francis, J. N.; Redman, J. S.; Paul, S.; Weinstock, M. T.; Reeves, J. D.; Lie, Y. S.; Whitby, F. G.; Eckert, D. M.; Hill, C. P.; Root, M. J.; Kay, M. S. Design of a potent D-peptide HIV-1 entry inhibitor with a strong barrier to resistance. J. Virol., 2010, 84(21), 11235-11244.
132. Munch, J.; Standker, L.; Adermann, K.; Schulz, A.; Schindler, M.; Chinnadurai, R.; Pohlmann, S.; Chaipan, C.; Biet, T.; Peters, T.; Meyer, B.; Wilhelm, D.; Lu, H.; Jing, W.; Jiang, S.; Forssmann, W. G.; Kirchhoff, F. Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. Cell, 2007, 129(2), 263-275.
133. Purtscher, M.; Trkola, A.; Grassauer, A.; Schulz, P. M.; Klima, A.; Dopper, S.; Gruber, G.; Buchacher, A.; Muster, T.; Katinger, H. Restricted antigenic variability of the epitope recognized by the neutralizing gp41 antibody 2F5. AIDS, 1996, 10(6), 587-593.
134. Zwick, M. B.; Jensen, R.; Church, S.; Wang, M.; Stiegler, G.; Kunert, R.; Katinger, H.; Burton, D. R. Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1. J. Virol., 2005, 79(2), 1252-1261.
135. Huang, J.; Ofek, G.; Laub, L.; Louder, M. K.; Doria-Rose, N. A.; Longo, N. S.; Imamichi, H.; Bailer, R. T.; Chakrabarti, B.; Sharma, S. K.; Alam, S. M.; Wang, T.; Yang, Y.; Zhang, B.; Migueles, S. A.; Wyatt, R.; Haynes, B. F.; Kwong, P. D.; Mascola, J. R.; Connors, M. Broad and potent neutralization of HIV-1 by a gp41- specific human antibody. Nature, 2012, 491(7424), 406-412.
136. Huang, J.; Kang, B. H.; Pancera, M.; Lee, J. H.; Tong, T.; Feng, Y.; Imamichi, H.; Georgiev, I. S.; Chuang, G. Y.; Druz, A.; Doria- Rose, N. A.; Laub, L.; Sliepen, K.; van Gils, M. J.; de la Pena, A. T.; Derking, R.; Klasse, P. J.; Migueles, S. A.; Bailer, R. T.; Alam, M.; Pugach, P.; Haynes, B. F.; Wyatt, R. T.; Sanders, R. W.; Binley, J. M.; Ward, A. B.; Mascola, J. R.; Kwong, P. D.; Connors, M. Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. Nature, 2014, 515(7525), 138-142.